Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to a decrease in the revenue from non-invasive prenatal genetic testing and challenges in the international market [1][5]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.63 billion yuan, a decrease of 12.82% compared to the same period last year [1]. - The net profit attributable to shareholders was approximately 5.78 million yuan, down 68.25% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was approximately -30.49 million yuan, reflecting a drastic decline of 2,610.77% [1]. - The net cash flow from operating activities was -413.84 million yuan, a decrease of 414.23% compared to the previous year [1]. - Basic earnings per share were 0.0139 yuan, down 67.90% year-on-year [1]. Business Segments - Revenue from non-invasive prenatal genetic testing decreased by approximately 35% due to a slight decline in sample volume [5]. - The reproductive health business saw a 15% increase in revenue from genetic testing for hereditary diseases in the clinical diagnosis sector [5]. - The company achieved significant growth in overseas markets, particularly in Latin America, where revenue from non-invasive prenatal genetic testing showed strong momentum [5][6]. - The single-cell sequencing business within the multi-omics segment experienced a notable revenue increase of approximately 110% [5]. Strategic Initiatives - The company is focusing on enhancing its product offerings in high-margin areas to counteract the price decline of basic non-invasive prenatal testing products [5]. - Efforts are being made to expand the sales layout for colorectal cancer detection products in the consumer market [5]. - The introduction of a fully automated local solution for high-throughput pathogen sequencing aims to meet the detection needs of various medical institutions [5].